December 8, 2025Blood
Low-dose oral decitabine and cedazuridine among patients with low-risk myelodysplastic syndromes
Authors
Discussion
Loading...
Member takes
Implication
Randomized trial reports hematologic response in low-risk myelodysplastic syndromes, suggesting low-dose therapy may enhance safety.
Key Points
- Evaluate the efficacy and safety of low-dose oral decitabine and cedazuridine for treating low-risk myelodysplastic syndromes.
- Randomized, open-label clinical trial
- Involved adults with low-risk myelodysplastic syndromes
- Compared low-dose and standard-dose regimens of DEC-C
- 42.5% of low-dose and 28.6% of standard-dose patients continued treatment at cutoff
- Median overall survival was longer in standard-dose compared to low-dose regimens
- Both regimens exhibited comparable hematologic response, but low-dose showed fewer adverse events.
Cite This Study
Garcia‐Manero et al. (2025) studied this question.